Background: Perfluoroalkyl substances (PFASs) have been frequently used for many years in industrial and 29 consumer products. Maternal cigarette smoking may be associated with maternal PFAS levels. Further, 30 prenatal exposure to PFASs is suggested impact on human fetal development and may have long-term 31 adverse health effects later in life. Fetal exposure has previously been estimated from umbilical cord 32 plasma, but the actual concentration in fetal organs has never been measured. 33
Introduction 68
Perfluoroalkyl substances (PFASs) are slowly degradable pollutants and belong to the group of water-and 69 grease resistant fluorosurfactants used for many industrial and consumer applications, like outdoor clothes, 70 non-stick cookware, food packaging, electronics, stain-resistant carpets and in fire-fighting foams (Key et 71 al., 1997; Jensen and Leffers, 2008; De Solla et al., 2012) . The PFASs include perfluorooctanesulfonic acid 72 (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA) and 73 perfluoroundecanoic acid (PFUnDA), all of which suspected to have negative impact on fetal growth and 74 development and may disturb the endocrine system ( de Cock et al., 2014; Johnson et al., 2014; Bach et al., 75 2015 ) . Prenatal exposure to PFOS and PFOA has been associated with an increased risk of congenital 76 cerebral palsy in Danish boys (Liew et al., 2014) and maternal exposure to PFNA and PFDA has been 77 associated with increased risk of pregnancy lost (Jensen et al., 2015) . In rodents, prenatal exposure to high 78 doses of PFOS and PFOA reduced postnatal survival and birth weight, and disturbed lactation and growth of 79 the pups (Lau et al., 2004; Olsen et al., 2009 ) and both pre and postnatal PFASs exposure have been 80 associated with hypothyroidism and significant decreased T4 levels in pups (Yu et al., 2009) . 81
PFASs, and particularly PFOA and PFNA, have been shown to induce synthesis of the estrogen-responsive 82 biomarker protein vitellogenin leading to an estrogen-like activity in vivo in rainbow trout (Benninghoff et 83 al., 2011) . 84 85 Notably, PFASs half-life in rats is as short as a few days (Kudo et al., 2002) , compared to 200 days in the 86 cynomolgus monkey (Seacat et al., 2002) , and 2.5-4.5 years in humans (Olsen et al., 2007; Zhang et al., 87 2013 ), suggesting a large difference in the elimination kinetics between species, and therefore animal 88 models may only reflect the human situation to a limited extent. 89 90 Human fetal exposure has been estimated from levels measured in maternal circulation and umbilical cord 91 blood in newborns. Prenatal exposure to PFOA has been associated with decreased birth weight in a dose 92 dependent manner (Johnson et al., 2014; Lauritzen et al., 2017 ). An association between PFOS exposure 93 and birth weight has also been suggested, but reported results are conflicting (Bach et al., 2015) whereas 94 prenatal PFOS and PFOA exposure has been suggested to negatively affect thyroid function. In new-born 95 boys, T4 levels decreased with increasing prenatal exposure to PFOS and PFOA. Surprisingly, the same study 96 found the opposite effect in girls where the T4 level increased with increasing prenatal exposure to PFOA 97 (de Cock et al., 2014) . In human breast cancer cells, PFOA are suggested to be cytotoxic and to exert an 98 estrogen effect, though an anti-estrogen effect was found when cells were co-exposed to estradiol (Henry 99 and Fair, 2013). Information on the actual concentration of PFASs in human tissues is limited, but a few 100 5 reports do exist (Olsen et al., 2003a; Maestri et al., 2006; Kärrman et al., 2010; Pérez et al., 2013) . Lung 101 tissue is suggested to accumulate the highest concentration of PFASs in general, though PFOS and PFOA 102 tend to accumulate with highest prevalence in liver and bone structures, respectively (Pérez et al., 2013) . In 103 liver, PFOS was detected in higher concentrations than PFOA (Maestri et al., 2006; Kärrman et al., 2010; 104 Pérez et al., 2013) . In human liver, PFOA has been detected in higher levels than PFNA and PFDA in one 105 report (Pérez et al., 2013) and in similar levels in another (Kärrman et al., 2010) . PFASs were found in all 106 human tissues (Pérez et al., 2013) . The tissue concentrations in human fetal organs are currently not 107 available. 108 109 Maternal cigarette smoking, together with other lifestyle parameters, may impact maternal PFAS levels 110 (Lauritzen et al., 2016) , why the present study included maternal smoking and other lifestyle factors in 111 order to evaluate if maternal lifestyle affected maternal and fetal PFAS levels. Cotinine is the primary 112 metabolite of nicotine and is a valid biomarker used to discriminate smokers from non-smokers (Benowitz 113 et al., 2003) . The adverse effects that maternal smoking has on the unborn child is well-known and widely 114 described (Mund et al., 2013) . Plasma cotinine concentrations in newborns have been reported to be 115 approximately 60 ng/mL in children of heavy smokers, 30 ng/mL in children from moderate smokers, and 3 116 ng/mL in children from non-smokers (Ivorra et al., 2014) . The actual concentrations in human fetuses have 117 not previously been measured. 118
119
The present study is, to our knowledge, the first to measure the actual concentrations of PFASs and 120 cotinine in human first trimester fetuses. These findings provide (i) important new knowledge on the 121 perfusion of PFASs and cotinine from mother over the early placenta barrier to fetal circulation and organs, 122 and (ii) evaluate if fetal age is associated with fetal PFASs levels indicating a fetal accumulation over time 123 and (III) whether maternal cigarette smoking affects PFASs accumulation in mother and fetus. 124
Materials and Methods 125

Participating women 126
The participants were healthy women aged 18-46 years (mean ±SEM, 26.4 ±1.1), who had decided to 127 terminate pregnancy for other reasons than fetal abnormality. Exclusion criteria: age under 18 years, 128 chronic diseases, dependency on an interpreter. The project was approved by the Research Ethics 129
Committees of the Regional Capital (H-KF 01 258206); all participants received oral and written information 130 and gave their informed consent. The participants answered a detailed questionnaire concerning lifestyle 131 habits during pregnancy, including smoking and drinking habits. 132 6
Human fetal tissues and maternal blood samples 133
Legal abortions were performed at the Department of Obstetrics and Gynaecology, University Hospital 134 Skejby, Denmark and at Department of Obstetrics and Gynaecology, Regional Hospital Randers, Denmark, 135 in collaboration with the Laboratory of Reproductive Biology, Rigshospitalet, Denmark. All fetuses were 136 morphologically normal. Within one hour after the surgical procedure the fetal organs and placenta tissue 137 were isolated, washed in sterile saline snap frozen on dry ice, and stored at -80 °C until analysis. Fetal 138 organs and placenta tissue processed for freezing more than one hour after collection were not included in 139 the present study. Fetal age was measured by crown-rump lengths via ultrasound in connection with the 140 surgical procedure. Gestational age was converted to age post conception by subtracting two weeks. 141
Maternal blood samples were obtained in connection with anaesthesia prior to surgery, collected in 142 ethylenediamine tetraacetic acid (EDTA) tubes, and kept on ice until centrifugation (4.000g for 15 min) to 143 isolate plasma. Plasma was aliquoted to 200 µl microinserts in 1.5 mL vials (Skandinaviska GenTec, Västra 144 Frölunda, Sweeden) and stored at -20°C until analysis. 145 
Analysis of PFASs and cotinine 155
The analyses of PFOS, PFOA, PFNA, PFUnDa, PFDA and cotinine in the plasma, placenta and fetal tissues 156 samples were performed by LC/MS/MS (QTRAP 5500; AB Sciex, Foster City, CA, USA coupled to a liquid 157 chromatography system (UFLCXR, Shimadzu Corporation, Kyoto, Japan) according to procedures set out by 158
Lindh et al. (Lindh et al., 2012) . Plasma samples for calibration standards were obtained from healthy 159 volunteers at the laboratory in Lund. Plasma was also used as a proxy matrix for the tissue samples. The 160 levels were quantified and samples with low amounts of all compounds were selected for the calibration 161 standards. Calibration standards were prepared by adding a standard solution containing all analyzed 162 compounds. Concentrations were determined by peak area ratios between the analytes and the IS. The 163 levels of all compounds in the pooled serum used for preparation of standards were quantified in each 164 batch, and the calibration standards were corrected for the concentration found in this sample. Also, all 165 values were corrected for the chemical blank. The limit of detection (LOD) was determined as the 166 concentration corresponding to three times the standard deviation of the ratio of the peak at the same 167 retention time as the analyzed compounds, and the corresponding IS determined in the chemical blank 168 samples. Tissue extraction time was tested for 5, 15, 30, 45 min. It was found that after 30 min. no 169 additional chemicals were extracted from the tissue, and a 30 min. extraction time was subsequently used 170 for all samples included in the present study. To make sure the study set-up was not contaminated with 171 other chemicals, blank samples (IS solution) were included for all batches of tissue prepared and treated 172 exactly the same way as the actual samples (see section 2.3. A direct measurement of PFAS levels in fetal blood cannot be performed as it is not possible to obtain blood 187 samples from fetuses at these early developmental stages. Fetal organs were used instead and their PFASs 188 content compared to levels present in maternal circulation. Previously, PFOS have been measured in serum 189 and liver tissue and a mean liver to serum ratio was reported to 1.3 to 1 in adults (34-70 years) (Olsen et 190 al., 2003b) . However, PFOS has been found in the higher concentration in liver compared to other organs 191 (Pérez et al., 2013) . Taken together, these finding suggest similar concentrations in serum and tissues and it 192 is unlikely that the comparison between maternal plasma (mL) and fetal organs (g) significantly affects the 193 results. The number of fetal organs obtained from the same fetus was limited why a potential organ 194 specific accumulation cannot be evaluated. 195
196
Results 197
Thirty-nine women were included in this study and a total of 34 placenta samples, 108 fetal organs and 24 198 blood samples were obtained from the participants (for detailed distribution see Fig. 1 ). The 108 organs 199 were obtained from a total of 36 fetuses aged 37-68 days pc (mean ±SEM, 52 ±1.3)( Fig. 1) . 200 201 3.1. Cotinine concentrations in plasma, placenta, and fetal organs 202 A plasma cut-off value of 3 ng/mL was used to discriminate between smokers and non-smokers (Benowitz 203 et al., 2009) . Three participants reported themselves as non-smokers but presented with cotinine levels 204 above the cut-off value. They were grouped as smokers and their questionnaire excluded from analysis. 205
Women who smoked had significantly higher levels cotinine levels in maternal plasma, placenta, and fetal 206 organs compared to non-smokers (p<0.001, p<0.0001, p<0.0001, respectively). Mean plasma levels (±SEM) 207 in smokers were 99.3 ng/g ± 26.9, range: 6.2-326.1 ng/g, and in non-smokers 0.2 ng/g ± 0.1; range: 0-1.1 208 ng/g ( Table 2 ). Cotinine concentration in smoke-exposed placentas was 107.8 ng/g ±22.3; 3.8-374.7 (mean 209 ±SEM; range) and in non-exposed placentas 0.4 ng/g ±0.1; 0.0-1.8 (mean ±SEM; range) ( Table 2) . Cotinine 210 levels in smoke-exposed and non-exposed fetal organs were 61.1 ng/g ±9.2; 1.1-336 (mean ±SEM; range) 211 (p<0.0001) and 0.4 ng/g (range: 0-2.6), respectively (Table 2) . Cotinine was detected in all different fetal 212 organs exposed to cigarette smoke (Fig. 2) . Cotinine was hardly detectable in the placentas and fetal organs 213 of non-smokers (Fig. 2) . In the group who smoked, a significant positive correlation was found between 214 fetal age and the fetal to maternal cotinine ratio (p=0.0168) (Fig 3. ). There were no association between the 215 number of cigarettes smoked and the cotinine concentration in fetal tissue (p>0.1) (data not shown). 216
Maternal plasma, placenta and fetal organs from the same women were available in 21 cases. From each 217 woman, the mean cotinine concentration (ng/g) in fetal organs was calculated and the overall mean 218 presented ( Table 3 ). The percentage was calculated as concentrations in fetal organs and placenta 219 respectively in relation to the corresponding maternal plasma (100%) ( (Fig. 3) . Further, 224 significantly linear correlations were found for PFOS (p=0.0011), PFNA (p=0.0243), and PFUnDA (p=0.0467) 225 ( Fig. 3) . 226
The concentration of PFASs in maternal plasma, placenta, and fetal organs was presented in Table 2 . The 227 PFAS levels in plasma from women who smoked were higher compared to women who did not smoke, 228 though not at a significant level for any of the PFASs. All five measured PFASs were present in the evaluated 229 fetal organs. No association between maternal plasma cotinine levels and plasma PFASs was found (p>0.1). 230 231 Maternal plasma, placenta tissue and fetal organs were available for each of 21 cases. PFASs in placenta 232 and fetal organs were greatly reduced compared to maternal plasma. The relative concentrations of PFOS, 233 PFOA, PFNA, and PFUnDA in placentas were 11-15% of the concentration found in maternal plasma, and 234 were further reduced to 5-13% in fetal organs (Table 3) . PFDA was detected in relatively higher 235 concentration in placenta (43%) and fetal organs (27%) compared the other PFASs (Table 3) . PFOS in 236 maternal plasma was significantly higher compared to the other PFASs measured. Interestingly, PFOS was 237 detected in the lowest relative concentration in fetal organs (5%) ( Table 3) . 238 239
Correlation between lifestyle and PFAS levels 240
Maternal characteristic and life-style habits were presented in Table 1 . The concentrations of PFNA and 241
PFUnDA showed a significant negative association with BMI (p=0.0391; p=0.0085, respectively) ( Fig. 4) , 242
while there was no significant association between BMI and fetal PFASs levels (p>0.1) and between PFASs 243 and maternal cigarette smoking, maternal age, or rual/urban residence (P>0.1). 244 245 Further, a positive correlation (over 50%) was found between first-hand smoking and second-hand smoking 246 (r=0.65, p<0.0001), second-hand smoke smoking also correlated positively with fathers smoking habits 247 (r=0.50, p=0.004) (Supp. 
Discussion 253
These data demonstrate that PFASs and cotinine are transferred from mother to fetus during the first 254 trimester of pregnancy and that fetal PFASs levels increase with fetal age, suggesting that these substances 255 may accumulate in the fetus during gestation. All five evaluated PFASs were significantly higher in maternal 256 circulation as compared to fetal levels. Further a negative correlation between maternal BMI and plasma 257 concentrations of PFNA and PFUnDA were found supporting previous reports (Lauritzen et al., 2016) . 258
Collectively, these data provide information on the exact PFAS concentrations present in fetal organs, 259 placenta, and maternal plasma during first trimester of pregnancy together with the transfer rate from 260 mother to fetus. 261
Fetal age correlated positively with fetal concentrations of all five PFASs 262
Fetal age correlated positively with fetal concentrations of all five PFASs evaluated, suggesting that these 263 compounds accumulate in the fetal tissues and may continue to increase during pregnancy. It has been 264 shown that phthalates and PFOS accumulate in the human amniotic fluid during the second trimester at 265 almost 10% per gestational week (Jensen et al., 2012) , supporting the present findings. Given that the 266 development of keratinized epidermal skin is first seen in human fetuses from week 22 pc (Hardman et al., 267 1999 ), the fetal skin will prior to this age be permeable and chemicals from the amniotic fluid may be 268 absorbed by this route. Hence in early pregnancy the fetus may be exposed to PFASs from both placental 269 blood and from the amniotic fluid. 270 271
PFASs in human fetal organs in relation to maternal levels 272
The five PFASs were detected in all the different fetal organs evaluated indicating that fetuses are 273 systemically exposed to these compounds. Although the majority of the organogenesis are completed 274 around weeks six to eight (Zhou et al., 2012) , the organs are still at an early immature stage, and an 275 organ-specific accumulation is not expected at this early age. In adults, PFOA and PFOS accumulate in liver 276 and bone structures (Pérez et al., 2013) , further all the five PFASs evaluated in the present study have been 277 detected in adult liver tissue (Kärrman et al., 2010) suggesting that the tissue accumulation the present 278 study find in fetal life continues in adulthood. 279
The concentrations of PFOS, PFOA, PFNA, and PFUnDA in placenta were reduced to 11-15% of the 280 concentrations found in the maternal circulation. These levels were further attenuated across the placenta 281 to the fetal organs, to a level of 5-13% of the concentration found in maternal plasmas, indicating that the 282 fetal exposure to these compounds was 7-20 times lower than the maternal levels. Of the PFASs 283 examined, PFDA were found in the lowest concentrations in maternal plasma, but showed the relative 284 highest concentration in both placenta (43%) and fetal tissues (27%) as compared to maternal plasma. 285
Although the assay of measurement is close to the detection limit, these values are within the standard 286 curve and are considered valid. These data suggest that PFASs accumulate in fetal tissue with different 287 efficiency. The differences in in fetal uptake may be due to different placental clearance or fetal age. present study detected actual fetal concentration of PFASs to be 3-12 times lower than the previous 292 estimated from umbilical cords, which may either reflect that fetal PFAS levels increase during gestation 293 (the present study find a significantly positive correlation between PFASs and fetal age), or indicate that the 294 actual fetal exposure may be less than previously anticipated. 295
PFAS levels in maternal plasma 296
In maternal plasma, PFOS were present in the highest concentration of all PFASs measured followed by 297 PFOA. The lowest concentrations were found in PFNA, PFUnDa, and PFDA, respectively. These findings 298 were reflected in the levels measured in the fetal organs, where PFOS and PFOA also were preset in highest 299 concentrations followed by PFNA, PFUnDa, and PFDA. The maternal PFAS levels support previous 300 PFOA in plasma. In a study of 1,400 women, plasma levels of PFOS and PFOA were 4 and 8 times higher 305 than the present study (Fei et al., 2007) whereas Hannsen and colleagues reported 5 and 1.5 times the 306 concentrations of the present study (Hanssen et al., 2010) . These differences may be explained by 307 variations in local exposure or by the year in which the samples were taken; during the last decade 308 changing levels of PFASs have been observed (Glynn et al., 2012; Olsen et al., 2012) . 309
We found a negative correlation between maternal BMI and the levels of PFNA and PFUnDA in maternal 310 plasma, though the correlation disappeared when compared to fetal levels, suggesting that maternal BMI 311 does not affect the PFNA and PFUnDA levels in the fetus. Maternal cigarette smoking was associated with 312 slightly higher plasma concentration of all five PFASs, but not to a significant level. Conflicting results of the 313 association between maternal cigarette smoking and maternal PFASs levels has been reported (Cho et al., 314 2015; Lauritzen et al., 2016 Lauritzen et al., , 2017 and the effect of maternal cigarette smoke may be questionable. 315
Nevertheless, this association was not reflected in placenta and fetal tissues, suggesting that smoking did 316 not affect the levels of PFASs transferred to the fetus. The included women were recruited from both rural 317 and urban areas, and no association was found between where the women were resident and her plasma 318 levels of PFASs, suggesting that exposure to pollutants from urban living does not impact PFAS levels in 319 pregnant women in Denmark. 320
Health compromising PFASs levels 321
Dietary intake has been suggested as the primary source of PFASs exposure (Domingo, 2012; Lauritzen et 322 al., 2016) with the largest contribution coming from meat, animal fat, and snacks (Halldorsson et al., 2008) . 323
The EFSA CONTAM panel has established a tolerable daily intake (TDI) for PFOS and PFOA of 150 ng/kg/day 324 and 15 µg/kg/day, respectively, based on the lowest non-observed adverse effect level identified in animal 325 exposure studies. The estimated intake of PFOS and PFOA in the present study was 2.7 and 2.1 respectively, 326 which is well below advised TDI. In the Swedish adult population the mean dietary PFAS exposure has been 327 estimated to 0.6-8.5 ng/kg/day (Domingo, 2012) , which is also well below the estimated health 328 compromising levels and suggests a minimal health risk at these levels in Scandinavian adults. PFOS and 329 PFOA plasma levels in Swedish women were 10.2 ng/mL and 2.9 ng/mL, respectively (Axmon et al., 2014) , 330 which is slightly higher than the maternal plasma levels in the present study. This can be interpreted as 331 neither the Swedish nor the present Danish plasma levels being health compromising in adult women, 332
given that uptake from other sources than diet is insignificant. However, the health compromising levels of 333
PFASs during fetal live is to our knowledge not defined. In pregnant women, plasma PFOA levels above 3.9 334 ng/mL was significantly associated with reduced birth weight (Fei et al., 2007) , suggesting that health 335 compromising levels may be lower in fetal life compared to adulthood. 336 337
PFASs and lifestyle 338
We did not find a correlation between the evaluated self-reported lifestyle parameters except between 339 smoking, second-hand smoke and fathers smoking habits, indicating that smokers are more likely to be 340 surrounded by other smokers, and may therefore expose their fetus to more cigarette smoke than their 341 personal cigarette consumption indicates. For all other aspects the lifestyles of the participants were 342 similar. The variation in PFAS concentrations between fetuses could not be explained by the monitored 343 lifestyle parameters: smoking habits, coffee-, tea-, soft drink, soft drink light -consumption, or exercise. 344
Fetal age was found to significantly correlate with PFAS levels in fetal organs and may be the most likely 345 explanation for the variation between fetuses. Differences in placental clearance may also impact on the 346 fetal PFAS levels. 347 348 4.6. Cotinine concentration in maternal plasma, placenta, and fetal organs 349 Among smokers, cotinine was detected in significantly higher concentrations in fetal organs compared to 350 PFASs. Cotinine accumulated in placenta and 106% of the concentration found in maternal plasma was 351 detected in placenta. The concentrations in smoke-exposed fetal tissues were reduced to 52% of the 352 concentration found in maternal plasma, indicating that cotinine crosses the placenta relatively easy and 353 reaches the fetal circulation. The mean concentration of cotinine in smoke-exposed fetuses was 61.1 ng/g, 354 which was very close to the concentration previously measured in serum from newborns of heavy smokers 355 (59.1 ng/mL) (Ivorra et al., 2014) . This may indicate that even though cotinine reaches the fetus in high 356 concentrations, its clearance is rapid (half-life: 16 hours, total clearance: 48 hours (Benowitz and Jacob, 357 1994)) compared to PFASs (≈4 years). Where PFAS tends to accumulate in the fetus, cotinine levels may 358 rather reflect the actual maternal level, which diffuses to the fetus. The highest cotinine concentration was 359 detected in fetal liver, which was close to the same concentration found in the placenta, indicating that 360 cotinine may accumulate in the liver. The lowest cotinine concentration was found in the ribs, likely 361 reflecting that cotinine reaches more perfused organs easier than bone structures. 362 363
Conclusions 364
In conclusion, the present study provides actual measurements on PFASs and cotinine concentrations in 365 human fetuses, together with comparisons to placenta and maternal plasma samples. Fetal age was 366 positively correlated with all evaluated PFASs, suggesting a fetal accumulation over time. In maternal 367 plasma PFOS levels were more than 4 times higher than PFOA, which were twice as high as PFDA, PFUnDa 368 and PFDA. The PFOS, PFOA, PFNA, and PNUnDA levels were reduced in placenta to 11-15% of the 369 concentration found in maternal plasma, and further reduced to 5-13%. In contrast PFDA, which was 370 present in the lowest concentrations of the evaluated PFASs in maternal plasma, was detected in the 371 relatively highest concentration in the fetus (27%), suggesting that the placenta retains PFASs with different 372 efficiency. These data suggest that fetal PFAS levels increase with fetal age, though the health 373 compromising level of these substances in fetal life is unknown. 374 
